JP2021521168A5 - - Google Patents
Info
- Publication number
- JP2021521168A5 JP2021521168A5 JP2020555449A JP2020555449A JP2021521168A5 JP 2021521168 A5 JP2021521168 A5 JP 2021521168A5 JP 2020555449 A JP2020555449 A JP 2020555449A JP 2020555449 A JP2020555449 A JP 2020555449A JP 2021521168 A5 JP2021521168 A5 JP 2021521168A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- preparation
- formulation
- controls
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013645 | 2018-04-10 | ||
| IN201841013645 | 2018-04-10 | ||
| PCT/IN2019/050291 WO2019198099A1 (en) | 2018-04-10 | 2019-04-10 | Stable antibody formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521168A JP2021521168A (ja) | 2021-08-26 |
| JP2021521168A5 true JP2021521168A5 (enExample) | 2022-04-15 |
Family
ID=68164052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555449A Pending JP2021521168A (ja) | 2018-04-10 | 2019-04-10 | 安定な抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12024561B2 (enExample) |
| EP (1) | EP3773695A4 (enExample) |
| JP (1) | JP2021521168A (enExample) |
| CN (1) | CN112243379A (enExample) |
| AU (1) | AU2019251452A1 (enExample) |
| BR (1) | BR112020020741A2 (enExample) |
| CO (1) | CO2020013545A2 (enExample) |
| SG (1) | SG11202009872YA (enExample) |
| WO (1) | WO2019198099A1 (enExample) |
| ZA (1) | ZA202006262B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040732B (zh) * | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| PE20120359A1 (es) * | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN112292146A (zh) * | 2018-04-10 | 2021-01-29 | 雷迪博士实验室有限公司 | 治疗性抗体的稳定的制剂 |
| SG11202009874QA (en) * | 2018-04-10 | 2020-11-27 | Dr Reddys Laboratories Ltd | Antibody formulation |
| AR119268A1 (es) * | 2019-06-10 | 2021-12-09 | Millennium Pharm Inc | Métodos de purificación de anticuerpos y composiciones de estos |
| CA3143167A1 (en) * | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Methods of producing an anti-.alpha.4.beta.7 antibody |
-
2019
- 2019-04-10 US US17/045,336 patent/US12024561B2/en active Active
- 2019-04-10 JP JP2020555449A patent/JP2021521168A/ja active Pending
- 2019-04-10 WO PCT/IN2019/050291 patent/WO2019198099A1/en not_active Ceased
- 2019-04-10 AU AU2019251452A patent/AU2019251452A1/en not_active Abandoned
- 2019-04-10 CN CN201980038032.1A patent/CN112243379A/zh active Pending
- 2019-04-10 SG SG11202009872YA patent/SG11202009872YA/en unknown
- 2019-04-10 EP EP19785443.3A patent/EP3773695A4/en active Pending
- 2019-04-10 BR BR112020020741-1A patent/BR112020020741A2/pt not_active IP Right Cessation
-
2020
- 2020-10-08 ZA ZA2020/06262A patent/ZA202006262B/en unknown
- 2020-10-28 CO CONC2020/0013545A patent/CO2020013545A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521159A5 (enExample) | ||
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| TWI653048B (zh) | 含有肉毒桿菌毒素的穩定液體組合物 | |
| JOP20210152A1 (ar) | صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf | |
| JP2021521171A5 (enExample) | ||
| JP2015525762A5 (enExample) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| WO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| Platts et al. | Control of globular protein thermal stability in aqueous formulations by the positively charged amino acid excipients | |
| JOP20220183A1 (ar) | صياغات أجسام مضادة ضد tslp بشرية وطرائق علاج مرض التهابي | |
| JP2013518808A5 (enExample) | ||
| WO2020246750A3 (ko) | 안정화된 핵산 면역증강제를 함유하는 약학 조성물 | |
| JP2024532736A5 (enExample) | ||
| RU2020136678A (ru) | Стабильная композиция антител | |
| WO2001048117A1 (fr) | Compositions seches contenant un acide amine hydrophobe | |
| RU2024113529A (ru) | Составы | |
| KR101699244B1 (ko) | 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물 | |
| RU2020136713A (ru) | Композиция из антител | |
| JP2023509354A5 (enExample) | ||
| IL312211A (en) | Formulations | |
| TW201607564A (zh) | 經安定化的多肽水性製劑 | |
| JP2024539502A5 (enExample) |